How Fear Can Show Us What’s Important

How Fear Can Show Us What’s Important

A few weeks ago, I had a long conversation with a stranger I met while traveling. She was a bold and smart young woman who shared tales of her solo trips as we flew. She insightfully concluded that travel had made her more resilient, aware, and resourceful. I agreed. Growing…

ANX005 Slows ALS Progression in Phase 2a Study

ANX005, an experimental medication being developed by Annexon Biosciences for neurodegenerative and autoimmune diseases, resulted in a slowing of disease progression in adults with amyotrophic lateral sclerosis (ALS). That’s according to preliminary data from eight patients taking part in a Phase 2a clinical study (NCT04569435), whose main…

Searching for Markers on the Difficult Path of ALS

I followed the directions on my phone to the Lily Creek Nature Sanctuary in Michigan’s Upper Peninsula. The 40-acre forest preserve with maple, paper birch, and balsam fir is only five minutes from my home, but I’d never been there. I’d seen an advertisement for a hike and…

Probiotic Prevents Neurodegeneration in ALS Worm Models

The bacterial strain Lacticaseibacillus rhamnosus HA-114 prevents neurodegeneration and preserves motor function in worm models of amyotrophic lateral sclerosis (ALS), a new study reports. This protective effect was linked to the fat molecules, called fatty acids, found in this strain, which helped restore fat metabolism in the mitochondria —…

Dosing Starts in First-in-human Phase 1 Trial of QRL-101 for ALS

A Phase 1 clinical trial has begun dosing adult healthy volunteers to investigate QurAlis Corporation‘s QRL-101, an oral treatment candidate for amyotrophic lateral sclerosis (ALS), the company announced. The first-in-human Phase 1 trial (NCT05667779) aims to assess the safety, tolerability, and pharmacokinetics — the movement of a…

Why Am I Singing Through a Straw, You Might Ask?

I’m always open to learning new things, especially when they involve simple ways to improve my life with ALS. When I come across something super helpful, I just have to share it with my readers. My most recent discovery involves a simple plastic straw. In fact, it’s become a…

Masitinib Gains Orphan Drug Status for ALS in Switzerland

Masitinib, an oral medicine developed by AB Science, has won orphan drug status for treating amyotrophic lateral sclerosis (ALS) in Switzerland. The status is granted by the Swiss Agency for Therapeutic Products (Swissmedic) to therapies that seek to treat life-threatening or chronic diseases affecting no more than…

Staying Grounded in a New Year While Living With ALS

On Saturday afternoon, I was feeling apprehensive that 2023 would be an even harder year for my husband, Todd, and me than previous ones. Todd’s breathing continues to weaken due to ALS. The beginning of the year is often a time when people take stock of their lives;…